This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Carcinoma in situ of lip, oral cavity and pharynx
CD2_INSITU_LIPORALPHARYNX_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D00
- Name in latin
- Carcinoma in situ labii (oris)
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of lip, oral cavity and pharynx
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of lip, oral cavity and pharynx
- Carcinoma in situ of oral cavity, oesophagus and stomach
- Carcinoma in situ of oral cavity, oesophagus and stomach
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 87 | 29 | 58 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.03 |
| Median age at first event (years) | 67.18 | 69.00 | 66.26 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 73
- Matched controls
- 729
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
EJA10
NOMESCO Finland
Biopsy of tongue or floor of mouth
98.8
24.8
26
*
D00.00
ICD-10 Finland
Cancer in situ on the lip red border
+∞
18.5
17
*
130
Kela drug reimbursment
Malignant tumour
+∞
16.2
15
*
C02.11
ICD-10 Finland
Malignant neoplasm of border of tongue
+∞
14.0
13
*
D00.06
ICD-10 Finland
Cancer in situ in another part of the tongue
+∞
14.0
13
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
36.2
13.7
17
6
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
7.5
13.4
39
97
EKA10
NOMESCO Finland
Biopsy of cheek
61.9
13.4
15
*
D00.09
ICD-10 Finland
Unspecified cancer in situ in oral cavity and throat
+∞
12.9
12
*
EJB10
NOMESCO Finland
Excision of lesion of apex or body of tongue
77.8
12.0
13
*
TEA00
NOMESCO Finland
Biopsy of lip
+∞
11.8
11
*
SBB00
NOMESCO Finland
Fotograf of mouth and teeth
17.9
11.7
18
13
ECA20
NOMESCO Finland
Biopsy of gingiva
127.6
10.7
11
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
+∞
10.7
10
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
+∞
10.7
10
*
EJB30
NOMESCO Finland
Excision of lesion of floor of mouth
+∞
10.7
10
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
63.8
9.9
11
*
SBA00
NOMESCO Finland
Microbiological examinations
25.9
9.7
13
6
K13.28
ICD-10 Finland
Other leukoplakia or disorder of epithelium of the palate or tongue
114.2
9.7
10
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
114.2
9.7
10
*
D00.04
ICD-10 Finland
In situ cancer of the floor of the mouth
+∞
9.6
9
*
A07AA02
ATC
nystatin; oral
11.7
8.8
16
17
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.5
8
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
+∞
8.5
8
*
K13.79
ICD-10 Finland
Change in the oral mucosa UNS
25.5
8.3
11
5
A03FA01
ATC
metoclopramide; systemic, rectal
7.6
8.1
19
32
EAA10
NOMESCO Finland
Excision of lesion of lip
50.6
7.9
9
*
K13.78
ICD-10 Finland
Other change in the oral mucosa
15.6
7.7
12
9
JN4BD
NOMESCO Finland
Extensive body CT
11.2
7.7
14
15
C03.0
ICD-10 Finland
Malignant neoplasm: Upper gum
+∞
7.4
7
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
7.4
7
*
D00.01
ICD-10 Finland
In situ cancer of the mucous membrane of the cheek
+∞
7.4
7
*
H02AB02
ATC
dexamethasone; systemic
33.7
7.3
9
*
SAA03
NOMESCO Finland
Extended examination of mouth
3.8
6.9
40
177
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
5.7
6.9
20
45
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
76.2
6.5
7
*
N02AA05
ATC
oxycodone; systemic
5.6
6.5
19
43
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
EAA30
NOMESCO Finland
Partial excision of lower lip
+∞
6.3
6
*
EKB00
NOMESCO Finland
Excision of lesion of cheek
+∞
6.3
6
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
6.3
6
*
C03.1
ICD-10 Finland
Malignant neoplasm: Lower gum
+∞
6.3
6
*
EDB00
NOMESCO Finland
Partial excision of mandible
+∞
6.3
6
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
6.3
6
*
C06.0
ICD-10 Finland
Malignant neoplasm: Cheek mucosa
+∞
6.3
6
*
D00.05
ICD-10 Finland
In situ cancer of the pharyngeal part of the tongue
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
51
6.84
13.69
2.8
2.1
0.2
0.2
g/l
0.33
26
39
10
9
12.35
5.96
3.4
1.1
—
—
—
0
0
49
262
2.99
5.92
5.6
3.5
—
—
—
0
0
30
126
3.11
5.51
3.3
1.9
—
—
—
0
0
21
80
3.14
4.46
6.9
6.5
0.5
1.7
mmol/l
0.73
16
63
24
104
2.81
4.05
2.8
1.7
—
—
—
0
0
13
40
3.65
3.80
7.6
8.3
0.5
0.8
%
2.07
13
40
15
53
3.21
3.57
2.1
1.4
—
—
—
0
0
6
6
10.61
3.55
1.3
1.3
—
—
—
0
0
24
113
2.55
3.41
2.4
2.3
0.3
1.0
e6/l
1.97
18
64
15
55
3.09
3.35
6.0
6.4
2.2
1.4
mmol/l
0.60
15
50
18
76
2.73
3.14
2.3
1.7
—
—
—
0
0
12
40
3.32
3.11
7.7
8.3
1.2
1.5
%
0.67
12
40
12
41
3.24
2.99
2.3
1.5
—
—
—
0
0
32
181
2.21
2.98
3.6
2.6
0.4
0.5
e6/l
0.09
26
130
17
72
2.69
2.95
3.2
2.7
19.5
7.5
umol/l
0.43
17
58
40
251
2.10
2.85
2.2
2.3
77.4
75.7
nmol/l
0.15
35
216
12
43
3.08
2.77
1.4
1.4
—
—
—
0
0
6
10
6.35
2.74
1.8
1.3
—
—
—
0
0
44
290
2.05
2.71
2.3
2.0
86.0
93.5
pmol/l
0.56
24
141
17
77
2.50
2.58
2.1
1.7
—
—
—
0
0
37
233
2.02
2.55
4.0
2.9
—
—
—
0
0
50
351
2.00
2.53
13.3
6.1
4.4
4.3
e9/l
0.06
45
295
6
12
5.28
2.44
1.8
1.3
—
—
—
0
0
15
70
2.38
2.13
4.9
2.4
218.8
235.2
u/l
0.42
15
64
16
82
2.17
1.84
10.9
8.1
—
—
—
0
0
6
18
3.50
1.78
3.5
1.4
—
—
—
0
0
6
19
3.31
1.69
1.8
1.0
—
—
—
0
0
17
93
2.03
1.66
2.6
2.3
15.8
23.3
%
1.80
12
84
6
20
3.14
1.61
4.5
1.9
—
—
—
0
0
5
15
3.47
1.54
1.0
1.2
—
—
—
0
0
13
67
2.11
1.47
5.4
3.6
1.7
2.6
mmol/l
0.30
13
52
18
105
1.90
1.47
2.8
2.6
1.5
3.0
e6/l
0.53
12
56
6
22
2.85
1.46
1.0
1.4
—
—
—
0
0
5
16
3.25
1.46
1.6
1.1
—
—
—
0
0
8
34
2.49
1.33
4.1
2.5
2.0
1.2
%
—
8
34
75
663
1.95
1.32
31.5
13.2
40.8
24.4
mg/l
2.05
62
508
8
36
2.34
1.28
8.0
7.2
23.6
25.7
mmol/l
—
8
36
11
58
2.03
1.18
2.1
2.0
334.0
384.7
nmol/l
0.32
11
50
8
40
2.10
1.15
1.3
2.0
—
—
—
0
0
21
142
1.63
1.05
1.4
1.8
1205.2
1204.4
nmol/l
0.00
16
111
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
5
22
2.35
1.05
2.8
1.5
0.2
0.3
u/ml
—
5
9
6
32
1.94
0.83
1.0
1.3
—
—
—
0
0
5
24
2.15
0.76
12.2
4.2
—
—
—
0
0
43
361
1.38
0.72
2.9
2.6
—
—
—
0
0
5
28
1.83
0.67
2.0
3.1
0.3
0.1
e6/l
—
5
28
0
21
0.00
0.61
0.0
1.5
—
2.6
—
0
13
6
35
1.77
0.59
1.2
1.9
—
—
—
0
0
32
269
1.30
0.50
3.8
3.4
13.3
24.7
%
5.28
12
124
35
300
1.28
0.47
4.7
3.9
21.0
59.6
ng/l
2.38
27
231
23
192
1.27
0.37
1.7
2.6
0.5
0.8
ug/l
1.44
14
127
8
62
1.32
0.29
1.3
1.5
—
—
—
0
0
5
73
0.67
0.27
4.0
3.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
2.4
—
0
5
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
45
424
1.13
0.17
5.0
3.0
79.9
48.7
u/l
1.30
45
395
72
701
1.16
0.14
37.6
15.7
84.8
83.2
umol/l
0.20
72
701
5
43
1.17
0.10
1.4
1.7
—
—
—
0
0
70
705
0.96
0.00
17.8
8.8
28.8
25.5
u/l
0.59
70
668
62
619
1.01
0.00
29.0
12.3
72.2
76.2
ml/min/173m2
0.73
56
490
23
234
0.98
0.00
4.6
3.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
109.7
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
102.0
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_LIPORALPHARYNX_EXALLC – Carcinoma in situ of lip, oral cavity and pharynx
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).